Dermatitis Clinical Trial
Official title:
Efficacy and Safety of the Association of Dexamethasone 0.5 mg + Clemastine Fumarate 1 mg When Compared to Dexamethasone 0.5 mg in Patients With Allergic Dermatitis
Verified date | November 2022 |
Source | Azidus Brasil |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Considering the pathogenesis of several allergic skin diseases to be investigated in this study as well as the pharmacodynamic mechanisms of the association of dexamethasone and clemastine fumarate, it is believed that the components of topical medication may act synergistically in the reduction of signs and symptoms of the diseases in question. Therefore it is expected that the association promotes results significantly superior to dexamethasone alone.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | November 2010 |
Est. primary completion date | November 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients who sign the Deed of Consent (IC) in two ways, by his own free will, agreeing with all study procedures; - Patients older than 18 years, any ethnicity, class or social group, regardless of sex; - Patients with pictures of dermatoses acute, subacute or chronic, of inflammatory origin and / or allergic, to which it is recommended the use of drugs under investigation topically, such as: - atopic dermatitis, - prurigo, - primary contact dermatitis or allergic - urticaria, - pharmacodermic, - allergic vasculitis, - dyshidrosis, Exclusion Criteria: - Patients being treated with antibiotics; - Participation in clinical trials in the 12 months preceding the survey; - Current treatment with immunosuppressants (eg, cyclosporine or methotrexate); - Current treatment with phototherapy (UVA, UVB, PUVA and lasers); - Use of systemic corticosteroids at inclusion visit or within 15 days prior to inclusion; - Topical treatments at the site of acne in the 15 days preceding the visit of inclusion; - Presence of any skin condition in areas affected by acne that hamper the evolutionary analysis of the lesion; - Presence of secondary infections at the site of treatment, diagnosed clinically; - Presence of other eczematous picture, such as nummular eczema, neurodermatitis, seborrheic dermatitis, psoriasis, scabies, and Buckley's syndrome Wiskott-Aldrich; - Pregnant or lactating women; - Chronic alcoholism; - Patients with a history of hypersensitivity to any component of the formulas of the products under investigation; - Any finding of clinical observation (clinical history or physical examination) that is interpreted by the physician investigator as a risk to the patient's participation in the study; - Allergic Dermatosis of moderate or severe that, according to the investigator, is not justified topical. |
Country | Name | City | State |
---|---|---|---|
Brazil | LAL Clinica Pesquisa e Desenvolvimento Ltda | Valinhos | São Paulo |
Brazil | LAL Clínica Pesquisa e Desenvolvimento Ltda | Valinhos | São Paulo |
Lead Sponsor | Collaborator |
---|---|
Azidus Brasil |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Through clinical examinations, evaluating the efficacy of the cream composed by 0.5 mg dexamethasone and clemastine 1mg compared with the cream of 0.5 mg dexamethasone in improving the signs and symptoms associated with allergic dermatitis. | 14 days | ||
Secondary | Improvement of the erythema associated with allergic dermatitis. | 14 days | ||
Secondary | Improvement of the edema associated with allergic dermatitis. | 14 days | ||
Secondary | Improvement of the extension of lesion associated with allergic dermatitis. | 14 days | ||
Secondary | Evaluate, through clinical examinations, the effectiveness of the drug association in reducing excoriation associated with allergic dermatitis. | 14 days | ||
Secondary | Evaluate, through clinical examinations, the effectiveness of the drug association in reducing exudation associated with allergic dermatitis. | 14 dyas | ||
Secondary | Evaluate, through clinical examinations, the effectiveness of the drug association in reducing of scabbing associated with allergic dermatitis. | 14 days | ||
Secondary | Evaluate, through clinical examinations, the effectiveness of the drug association in reducing of lichenification associated with allergic dermatitis. | 14 days | ||
Secondary | Evaluate the safety of the formulations in relation to the occurrence, type, frequency and intensity of adverse events during treatment. | 14 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03563066 -
Effect of Benralizumab in Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT02916888 -
A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists
|
N/A | |
Recruiting |
NCT01631617 -
Effects of Treatments on Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT03720470 -
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
|
Phase 3 | |
Recruiting |
NCT01012453 -
A Randomised Clinical Trial in a Population of Health Care Workers With Hand Eczema
|
N/A | |
Completed |
NCT00375713 -
Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema
|
Phase 3 | |
Completed |
NCT00001150 -
Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers
|
N/A | |
Completed |
NCT05247333 -
Implementation of a Minor Ailment Service in Community Pharmacy Practice
|
N/A | |
Withdrawn |
NCT04154033 -
Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone
|
Phase 2 | |
Completed |
NCT02979210 -
Infant Fecal Insult Study
|
N/A | |
Completed |
NCT02615912 -
A Single-Center, Exploratory Study to Analyze the Dynamics of Skin Microflora Following Exposure to Surfactants
|
N/A | |
Withdrawn |
NCT00746382 -
A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM)
|
Phase 2 | |
Terminated |
NCT00176956 -
Atopic Dermatitis-Like Skin Disease in Pediatric Heart Transplant Patients
|
Phase 3 | |
Completed |
NCT05001139 -
Clinical Investigation on the Efficacy and Safety of Relizema Ecofoam
|
N/A | |
Completed |
NCT00801502 -
Salmon in Pregnancy Study
|
N/A | |
Completed |
NCT00005781 -
Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles
|
N/A | |
Completed |
NCT05324618 -
Tacrolimus Versus Hydrocortisone in Atopic Dermatitis
|
Phase 4 | |
Completed |
NCT04826471 -
Clinical Investigation on the Performance and Safety of DermoRelizema Ecofoam
|
N/A | |
Recruiting |
NCT06436183 -
A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
Recruiting |
NCT05891743 -
Prevalence of Skin Sensitization and Dermatitis Among Epoxy-exposed Workers in the Wind Turbine Industry.
|